Special Issue "Tuberculosis, Drug and Diagnostics Development"
Deadline for manuscript submissions: 30 November 2020.
Interests: Pulmonary ;tuberculosis;diagnosis, resistance, treatment, nontuberculous mycobacteria
Despite the availability of anti-tuberculosis (TB) chemotherapy, TB remains a threat to public health and is the leading cause of death by a single infectious agent worldwide. Approximately 10 million people develop TB annually, and 1.6 million die from the disease. TB is a highly infectious disease; about 30% of persons in close contact with an infected individual become infected themselves, of whom about 5%–15% develop TB in their lifetime. The management of drug-resistant TB is also important; in this respect, disease outcomes are still unsatisfactory compared with those of drug-susceptible TB. Systematic meta-analyses have shown that resistance to first-line drugs reduces the probability of treatment success and increases the risk of acquiring resistance to other important drugs (multidrug-resistant TB). Drug-resistant TB generally requires a longer treatment course than drug-susceptible TB, which increases the disease burden. Therefore, early detection of TB is critically important. The worldwide prevalence and incidence of nontuberculous mycobacterial (NTM) infections are also increasing. It is important to further explore the distribution of this disease. NTM disease is radiographically very similar to TB, and early differentiation is very important. The purpose of this Special Issue is to update our knowledge of TB and NTM diagnosis and treatment. Researchers in the field are encouraged to submit original articles or reviews.Dr. Byung Woo Jhun
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- nontuberculous mycobacteria